Table 3.

Significant findings of multivariable linear regressions analyzing genetic associations between candidate gene SNPs and lipid profiles in aromatase inhibitor–treated participants, adjusted for age, BMI, race, change in plasma estradiol, and prior hormonal therapy and tamoxifen use

CohortLipid parameterModelGene (SNP)MAFHWE PNumber of HOMMinor alleleMean change, mg/dL (SE)P
All patients onTGRecessiveCYP19A1 (rs10046*)0.480.6334A−36.4 (7.8)0.0000069
letrozole (n = 160)TGRecessiveCYP19A1(rs2289105*)0.480.8734C−36.45 (7.8)0.0000074
TGRecessiveCYP19A1(rs3759811*)0.430.6125C−32.3 (9.0)0.00045
TGRecessiveCYP19A1(rs700518*)0.440.7529C−32.3 (8.4)0.00019
TGRecessiveCYP19A1(rs4775936*)0.411.026C−33.2 (8.9)0.00028
HDLAdditiveCYP19A1(rs4646*)0.271.011A−4.2 (1.16)0.00043
TGRecessiveCYP19A1(rs749292*)0.410.5124A−39.3 (8.6)0.000012
TGAdditiveCYP19A1(rs749292*)0.410.5124A−20.2 (4.7)0.000037
Patients on letrozoleHDLAdditiveCYP19A1(rs749292*)0.470.5810A6.7 (1.4)0.000037
taking LAM (n = 52)HDLAdditiveCYP19A1(rs1062033*)0.420.588G6.9 (1.5)0.000043
HDLDominantCYP19A1(rs1008805*)0.380.245G−6.6 (1.7)0.00037
HDLDominantCYP19A1(rs749292*)0.470.5810A9.5 (2.4)0.0003
HDLAdditiveCYP19A1(rs10046*)0.450.579G−6.2 (1.6)0.00046
HDLAdditiveCYP19A1(rs2289105*)0.450.579T−6.2 (1.6)0.00046

Abbreviations: A, adenine; C, cytosine; G, guanine; HOM, homozygotes; HWE, Hardy–Weinberg equilibrium; SE, standard error; T, thymine.